AbbVie Hopes to Maintain Humira Exclusivity Through Secondary Patents and Regulatory Barriers to Entry

Biotechnology Law Report Feb 2017, Vol. 36, No. 1: 9-16.
Source: Biotechnology Law Report - Category: Medical Law Source Type: research